Adeona Pharmaceuticals, Inc. (AEN), a development-stage, specialty pharmaceutical company, has dedicated its efforts to developing proprietary, late-stage drug candidates designed to treat autoimmune and central nervous system (CNS) diseases. The company’s strategy is to exclusively in-license proprietary, clinical-stage drug candidates that have proven clinical efficacy for the treatment medical diseases that are as of yet unattended to. For further information, visit the Company’s web site at www.adeonapharma.com.
- 18 years ago
QualityStocks
Adeona Pharmaceuticals, Inc. AEN)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Engages Nanosoft to Advance ONC010 Development Program
This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising.…
-
QualityStocksNewsBreaks – Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) Expands Coverage of Precision Cardiovascular Tests Through Atlas Healthcare Physicians
Cardio Diagnostics Holdings (NASDAQ: CDIO), an AI-powered precision cardiovascular medicine company, announced that Atlas Healthcare…
-
QualityStocksNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Expands Heidelberg R&D Facilities To Support Drug Development Pipeline
VERAXA Biotech (NASDAQ: VRXA) an emerging developer of novel cancer therapies, announced it has expanded…